Outlook Therapeutics announced that its ONS-5010 drug for wet age-related macular degeneration (AMD) did not meet the primary endpoint in the NORSE EIGHT clinical trial. Despite this setback, the company plans to resubmit its marketing application to the FDA in Q1 2025 based on ongoing data analysis and the drug’s favorable safety profile. The stock price has fallen significantly following the announcement.
The global gene therapy market for Severe Combined Immunodeficiency (SCID) is poised for significant growth, projected to reach $2 billion by 2034. Driven by advancements in gene therapy techniques, the market is witnessing an increase in collaborations and partnerships between pharmaceutical companies and research institutions. This article dives into the key trends shaping the market, highlighting successful treatments like Strimvelis and the potential of gene editing for SCID.
BioMarin Pharmaceutical (BMRN) is set to release its quarterly earnings on Tuesday, October 29th. Investors are eagerly awaiting the announcement, hoping for positive news on earnings per share, guidance for the next quarter, and overall company performance. This article provides a comprehensive analysis of BioMarin’s financial performance, market trends, and analyst insights to help investors prepare for the upcoming earnings release.
The global allergy treatment market is poised for substantial growth, driven by rising allergy prevalence, advancements in medical science, and evolving treatment options. This market is projected to reach a value of US$ 34.9 billion by 2034, expanding at a CAGR of 5.8%. Factors like changing lifestyles, poor air quality, and increasing pollution contribute to the rising number of allergy sufferers, fueling demand for effective treatments.
A reactor blast at a pharmaceutical company in Andhra Pradesh’s Atchutapuram SEZ has resulted in a tragic loss of life. The death toll has reached 17, with 33 others injured. President Murmu and Prime Minister Modi have expressed condolences, and the Prime Minister has announced ex-gratia payments to the families of the deceased.
Zahabiya Khorakiwala, daughter of Habil Khorakiwala, founder of Wockhardt, has taken the reins of the multinational pharmaceutical company’s hospital arm. She oversees Wockhardt Hospitals, a company valued at Rs 9517 crore, and has been instrumental in its growth and expansion. Her journey highlights the leadership and business acumen of the next generation in India’s corporate world.
